Cellular and cytokine responses of the human central nervous system to intracranial administration of tumor necrosis factor α for the treatment of malignant gliomas

Cancer Immunology Immunotherapy

Volumn 36, Issue 4, 1993, Pages 251-259

  Tada, Mitsuhiro ^a   Sawamura, Yutaka ^a   Sakuma, Shirou ^a   Suzuki, Kazuo ^b   Ohta, Hidemi ^c   Aida, Toshimitsu ^a   Abe, Hiroshi ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^c MOCHIDA PHARMACEUTICAL CO   (Japan)

Author keywords

Cytokine response; Intracranial injection; Leukocyte recruitment; Malignant glioma; Tumor necrosis factor

Indexed keywords

INTERLEUKIN 6; INTERLEUKIN 8; PROSTAGLANDIN E2; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CEREBROSPINAL FLUID; CLINICAL ARTICLE; GLIOMA; HUMAN; HUMAN TISSUE; INTRATUMORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; T LYMPHOCYTE;

ADULT; CHEMOTAXIS, LEUKOCYTE; DINOPROSTONE; GLIOMA; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMAN; INTERFERONS; INTERLEUKIN-1; INTERLEUKIN-2; INTERLEUKIN-6; MIDDLE AGE; NEUTROPHILS; TIME FACTORS; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR;

EID: 0027522903     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/BF01740907     Document Type: Article

References (57)

1. Vascular hyperpermeability induced by tumor necrosis factor and its augmentation by IL-1 and IFN-γ is inhibited by selective depletion of neutrophils with a monoclonal antibody
2. Intralesional application of recombinant human tumor necrosis factor α induces local tumor regression in patients with advanced malignancies
3. The immunological basis of endotoxin-induced tumor regression. Requirement for a preexisting state of concomitant anti-tumor immunity
4. Increased leukotriene C4 and vasogenic edema surrounding brain tumors in humans
5. Phase I study of recombinant tumor necrosis factor in cancer patients
6. An endotoxin-induced serum factor that causes necrosis of tumors
7. Clinical trials with human tumor necrosis factor: in vivo and in vitro effects on human mononuclear phagocyte function
8. A phase I clinical trial of recombinant human tumor necrosis factor
9. A phase I clinical trial of recombinant human tumor necrosis factor given daily for five days
10. Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1
11. Multiple biological activities of human recombinant interleukin 1
12. IL-1 and tumor necrosis factor synergistically stimulate fibroblast IL-6 production and stabilize IL-6 messenger RNA
13. A phase I clinical trial of intravenously-administered recombinant tumor necrosis factor-alpha in cancer patients
14. Comparison of in vitro cell cytotoxic assay for tumor necrosis factor
15. On the cellular source and function of interleukin 6 produced in the central nervous system in viral diseases
16. Tumor necrosis factor: immunologic, antitumor, metabolic, and cardiovascular activities
17. Stimulation of the adherence of neutrophils to umbilical vein endothelium by human recombinant tumor necrosis factor
18. Effects of interferon-gamma and tumor necrosis factor-alpha on clonogenic growth of cell lines and primary cultures from human gliomas and brain metastases
19. IL-6/IFN-β as a circulating hormone: induction by cytokine administration in humans
20. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas
21. Growth-promoting effect of recombinant interleukin 1 and tumor necrosis factor for a human astrocytoma cell line
22. The neutrophil-activating protein (NAP-1) is also chemotactic for T lymphocytes
23. Tumor necrosis factor alpha in cerebrospinal fluid during bacterial but not viral meningitis
24. Role of interleukin 6 in fever in rats
25. Modulation of the immune response to transplanted tumors in rats by selective depletion of neutrophils in vivo using a monoclonal antibody: abrogation of specific transplantation resistance to chemical carcinogen-induced syngenic tumors by selective depletion of neutrophils in vivo
26. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays
27. Recombinant human tumor necrosis factor α lacks chemotactic activity for human peripheral blood neutrophils and monocytes
28. Antitumor activity of recombinant interleukin 6 in mice
29. Cerebrospinal fluid prostaglandins, interleukin 1β, and tumor necrosis factor in bacterial meningitis
30. The inhibition of neoplastic cell proliferation with human natural tumor necrosis factor
31. Generation and decay of the immune response to a progressive fibrosarcoma
32. Inhibition of neutrophil migration by tumor necrosis factor. Ex vivo and in vivo studies in comparison with in vitro effect
33. Phase I study of intratumoral application of recombinant human tumor necrosis factor
34. Interleukin-1: biology, pathophysiology, and clinical prospects
35. Tumor necrosis factor alpha/cachectin and interleukin 1 beta initiate meningeal inflammation
36. Complete amino acid sequence of a human monocyte chemoattractant, a putative mediator of cellular immune reactions
37. Cytostatic and cytotoxic activity of tumor necrosis factor on human cancer cells
38. The effects of human recombinant tumor necrosis factor on glioma-derived cell lines: cellular proliferation, cytotoxicity, morphological and radioreceptor studies
39. The role of cytokines in the generation of inflammation and tissue damage in experimental gram-positive meningitis
40. Immunobiology of brain tumors
41. In vitro prostaglandin E2 production by glioblastoma cells and its effect on interleukin-2 activation of oncolytic lymphocytes
42. Selective attraction of monocytes and T lymphocytes of the memory phenotype by cytokine RANTES
43. Effects of recombinant tumor necrosis factor (rHuTNFα) on human neutrophils and monocytes: in vitro, ex vivo and in vivo
44. Biological and clinical effects of intravenous tumor necrosis factor-α administered three times weekly
45. Tumor necrosis factor: an update on basic research and clinical applications
46. Tumour necrosis factor in man: clinical and biological observations
47. Recombinant human tumor necrosis factor administered as five-day continuous infusion in cancer patients: phase I toxicity and effects on lipid metabolism
48. Recombinant human tumor necrosis factor administered as 24-h intravenous infusion. A phase I and pharmacologic study
49. Endothelial cell gene expression of a neutrophil chemotactic factor by TNFα, LPS, and IL-1β
50. Recombinant human tumor necrosis factor-α: Effects on proliferation of normal and transformed cells in vitro
51. Differences among primates in defence against infection: sensitivity of polymorphonuclear leukocytes to fMet-Leu-Phe
52. Purification and partial primary sequence of a chemotactic protein for polymorphonuclear leukocyte derived from human lung giant cell carcinoma LU65C cells
53. Human glioblastoma cells release interleukin 6 in vivo and in vitro
54. Interleukin-8 is produced in neoplastic and infectious diseases of the human central nervous system
55. Local production of tumor necrosis factor alpha, interleukin 1, and interleukin 6, in meningococcal meningitis. Relation to the inflammatory response
56. T cell suppressor factor from human glioblastoma cells is a 12.5-kd protein closely related to transforming growth factor-β
57. Effects of recombinant human tumor necrosis factor-α on the surface phenotype and the growth of human malignant glioma cell lines